Membranoproliferative glomerulonephritis primary prevention
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis primary prevention On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis primary prevention |
|
FDA on Membranoproliferative glomerulonephritis primary prevention |
|
CDC on Membranoproliferative glomerulonephritis primary prevention |
|
Membranoproliferative glomerulonephritis primary prevention in the news |
|
Blogs on Membranoproliferative glomerulonephritis primary prevention |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]
Overview
Effective measures for primary prevention of membranous glomerulonephritis include vaccination against hepatitis B and hepatitis C.
Primary Prevention
Effective measures for primary prevention of membranous glomerulonephritis include:[1][2]
- Vaccine against hepatitis B and hepatitis C.
References
- ↑ Lai, Kar Neng; Li, Philip K.T.; Lui, Siu Fai; Au, Tak Cheong; Tam, John S.L.; Tong, Kwok Lung; Lai, Fernand Mac-Moune (1991). "Membranous Nephropathy Related to Hepatitis B Virus in Adults". New England Journal of Medicine. 324 (21): 1457–1463. doi:10.1056/NEJM199105233242103. ISSN 0028-4793.
- ↑ Gyapay G, Jeney A, Lapis K (1985). "Drug action and chromatin structure. I. Adriamycin binding to core particle of nucleosomes and subsequent enhanced DNA fragmentation induced by micrococcal nuclease". Neoplasma. 32 (5): 521–8. PMID 4069286.